Back to Report Store Home

Global Gastrointestinal Drug Market to 2022 – Pipeline Characterized by Emerging Biologic Therapies, While TNF Inhibitors and PPIs Continue to Dominate Therapy Landscape

  • Published: Sep-2016
  • Report Code: GBIHC414MR
  • Report Format: pdf

Description

List of Tables

Table 1: Gastrointestinal Disorders, EU5 and US, Epidemiology of Gastrointestinal Disorders, 2015 17

Table 2: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Humira, 2016 25

Table 3: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Remicade, 2016 27

Table 4: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Soliris, 2016 28

Table 5: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Tysabri, 2016 30

Table 6: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Nexium, 2016 32

Table 7: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Entyvio, 2016 33

Table 8: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Protonix, 2016 35

Table 9: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Ocaliva, 2016 37

Table 10: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Dexilant, 2016 38

Table 11: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Amitiza, 2016 40

Table 12: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Takecab, 2016 42

Table 13: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Linzess, 2016 43

Table 14: Gastrointestinal Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($bn), 2015–2022 74

Table 15: Gastrointestinal Therapeutics Market, Global, Usage of Generics Across Key Indications, 2016 76

Table 16: Gastrointestinal Therapeutics Market, Global, Forecast Revenue by Company, 2015–2022 83

Table 17: Gastrointestinal Therapeutics Market, Global, Licensing Deals, 2006–2016 106

Table 18: Gastrointestinal Therapeutics Market Therapeutics Market, Global, Co-development Deals, 2006–2016 111

Table 19: Epidemiology Patterns for Gastroesophageal Reflux Disease, 2015–2022 117

Table 20: Epidemiology Patterns for Inflammatory Bowel Disease, 2015–2022 117

Table 21: Epidemiology Patterns for Inflammatory Bowel Disease, 2015–2022 117

Table 22: Gastrointestinal, Global, Table of all Clinical Stage Pipeline Products, 2016 118

Table 23: Abbreviations 159

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards